Kiniksa Pharmaceuticals International, plc

NasdaqGS:KNSA Stok Raporu

Piyasa değeri: US$1.5b

Kiniksa Pharmaceuticals International Yönetim

Yönetim kriter kontrolleri 4/4

Kiniksa Pharmaceuticals International CEO'su Sanj Patel, Jul2015 tarihinde atandı, in görev süresi 9.33 yıldır. in toplam yıllık tazminatı $ 5.30M olup, şirket hissesi ve opsiyonları dahil olmak üzere 16.3% maaş ve 83.7% ikramiyelerden oluşmaktadır. şirketin hisselerinin 2.38% ine doğrudan sahiptir ve bu hisseler $ 36.51M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.8 yıl ve 7.3 yıldır.

Anahtar bilgiler

Sanj Patel

İcra Kurulu Başkanı

US$5.3m

Toplam tazminat

CEO maaş yüzdesi16.3%
CEO görev süresi9.3yrs
CEO sahipliği2.4%
Yönetim ortalama görev süresi3.8yrs
Yönetim Kurulu ortalama görev süresi7.3yrs

Son yönetim güncellemeleri

Recent updates

Kiniksa Pharmaceuticals: Looking In On A Developing Growth Story

Oct 07

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Aug 07
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Kiniksa Pharmaceuticals: Improved Outlook For Arcalyst After Q2 Beat

Jul 24

Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Share Price Is Matching Sentiment Around Its Revenues

Jun 19
Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Share Price Is Matching Sentiment Around Its Revenues

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

Apr 25
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

Kiniksa Pharmaceuticals: Arcalyst Performs While Abiprubart Plans Take Shape

Apr 24

Kiniksa Pharmaceuticals, Ltd. Just Reported A Surprise Profit And Analysts Updated Their Estimates

Mar 01
Kiniksa Pharmaceuticals, Ltd. Just Reported A Surprise Profit And Analysts Updated Their Estimates

We're Not Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn

Feb 28
We're Not Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn

The Market Doesn't Like What It Sees From Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Revenues Yet

Dec 18
The Market Doesn't Like What It Sees From Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Revenues Yet

We're Interested To See How Kiniksa Pharmaceuticals (NASDAQ:KNSA) Uses Its Cash Hoard To Grow

Nov 10
We're Interested To See How Kiniksa Pharmaceuticals (NASDAQ:KNSA) Uses Its Cash Hoard To Grow

Investors Don't See Light At End Of Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Tunnel

Apr 18
Investors Don't See Light At End Of Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Tunnel

Investors Shouldn't Be Too Comfortable With Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Robust Earnings

Nov 10
Investors Shouldn't Be Too Comfortable With Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Robust Earnings

Industry Analysts Just Upgraded Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Revenue Forecasts By 27%

Aug 04
Industry Analysts Just Upgraded Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Revenue Forecasts By 27%

Kiniksa Pharmaceuticals GAAP EPS of -$0.29 beats by $0.15, revenue of $26.97M misses by $1.58M, reaffirms FY revenue guidance

Aug 03

Analysts Are Updating Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Estimates After Its First-Quarter Results

May 05
Analysts Are Updating Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Estimates After Its First-Quarter Results

We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate

Mar 18
We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate

Kiniksa: Latest Earnings Beat Shows Light At The End Of The Tunnel

Nov 25

Is Kiniksa Pharmaceuticals (NASDAQ:KNSA) A Risky Investment?

Nov 04
Is Kiniksa Pharmaceuticals (NASDAQ:KNSA) A Risky Investment?

Kiniksa: Unexciting, Slow Growth Stock

Aug 13

We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate

Jul 31
We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate

Kiniksa outlines development path for mavrilimumab after FDA feedback

Jun 08

Kiniksa: A Look At Mavrilimumab

May 03

Here's Why We're Not Too Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Situation

Apr 17
Here's Why We're Not Too Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Situation

CEO Tazminat Analizi

Sanj Patel'un ücretlendirmesi Kiniksa Pharmaceuticals International'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2024n/an/a

-US$9m

Jun 30 2024n/an/a

-US$10m

Mar 31 2024n/an/a

US$9m

Dec 31 2023US$5mUS$864k

US$14m

Sep 30 2023n/an/a

-US$7m

Jun 30 2023n/an/a

US$231m

Mar 31 2023n/an/a

US$196m

Dec 31 2022US$6mUS$835k

US$183m

Sep 30 2022n/an/a

US$143m

Jun 30 2022n/an/a

-US$112m

Mar 31 2022n/an/a

-US$134m

Dec 31 2021US$7mUS$803k

-US$158m

Sep 30 2021n/an/a

-US$175m

Jun 30 2021n/an/a

-US$189m

Mar 31 2021n/an/a

-US$184m

Dec 31 2020US$5mUS$780k

-US$161m

Sep 30 2020n/an/a

-US$140m

Jun 30 2020n/an/a

-US$123m

Mar 31 2020n/an/a

-US$122m

Dec 31 2019US$5mUS$780k

-US$162m

Sep 30 2019n/an/a

-US$173m

Jun 30 2019n/an/a

-US$170m

Mar 31 2019n/an/a

-US$153m

Dec 31 2018US$7mUS$740k

-US$103m

Sep 30 2018n/an/a

-US$93m

Jun 30 2018n/an/a

-US$85m

Mar 31 2018n/an/a

-US$76m

Dec 31 2017US$1mUS$700k

-US$65m

Tazminat ve Piyasa: Sanj 'ın toplam tazminatı ($USD 5.30M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 5.50M ).

Tazminat ve Kazançlar: Sanj 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Sanj Patel (55 yo)

9.3yrs

Görev süresi

US$5,297,067

Tazminat

Mr. Sanj K. Patel has been the Chief Executive Officer of Kiniksa Pharmaceuticals International, plc (formerly known as Kiniksa Pharmaceuticals, Ltd.) since July 2015. Before founding Kiniksa Pharmaceutica...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Sanj Patel
CEO & Chairman of the Board9.3yrsUS$5.30m2.38%
$ 36.5m
Eben Tessari
Senior VP & COO2.8yrsUS$1.75m0.14%
$ 2.2m
John Paolini
Senior VP & Chief Medical Officer8.3yrsUS$1.79m0.072%
$ 1.1m
Mark Ragosa
Senior VP & CFO3.9yrsVeri yok0.032%
$ 488.6k
Michael Megna
Chief Accounting Officer & Group VP of Finance4.8yrsVeri yok0.037%
$ 564.5k
Mei Jang
Senior Vice President of Technical Operations3.8yrsVeri yokVeri yok
Chad Morin
Senior VP & Chief Compliance Officer3.6yrsVeri yokVeri yok
Madelyn Zeylikman
SVP, General Counsel & Secretary3.8yrsVeri yokVeri yok
Carsten Boess
Executive Vice President of Corporate Affairsno dataVeri yokVeri yok
Martina Struck
Senior Vice President of Regulatory Affairs3.9yrsVeri yokVeri yok
Ross Moat
Senior VP & Chief Commercial Officer2.8yrsVeri yok0.030%
$ 462.5k
Joseph Pirrello
Chief Business Officerless than a yearVeri yokVeri yok

3.8yrs

Ortalama Görev Süresi

51.5yo

Ortalama Yaş

Deneyimli Yönetim: KNSA 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.8 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Sanj Patel
CEO & Chairman of the Board9.3yrsUS$5.30m2.38%
$ 36.5m
Kimberly Popovits
Independent Director6.8yrsUS$362.66k0.013%
$ 199.4k
Felix Baker
Lead Independent Director9.1yrsUS$411.06k0.040%
$ 608.3k
Thomas Malley
Independent Director7.9yrsUS$380.36k0.013%
$ 199.4k
Barry Quart
Independent Director9.1yrsUS$372.55k0.013%
$ 199.4k
Richard Levy
Independent Director5.7yrsUS$459.75k0.020%
$ 302.2k
G. Cole
Independent Director4.3yrsUS$365.36k0.013%
$ 199.4k
Stephen Biggar
Independent Director9.1yrsUS$371.96k0.012%
$ 186.1k
Robert Desnick
Chairman of Scientific Advisory Boardno dataVeri yok2.05%
$ 31.5m
Tracey McCain
Independent Director6.8yrsUS$365.36k0.013%
$ 199.4k
M. Boyd
Directorless than a yearVeri yokVeri yok

7.3yrs

Ortalama Görev Süresi

55.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: KNSA 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.3 yıldır).